SCHEMBL2367424

SCHEMBL2367424

O=C(O)N=Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
LMNA P02545 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
PLA2G7 Q13093 1/20 0.48
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
GRIN2D O15399 2/20 0.45
GRIN3B O60391 2/20 0.45
GRIN1 Q05586 2/20 0.45
GRIN2A Q12879 2/20 0.45
GRIN2B Q13224 2/20 0.45
GRIN2C Q14957 2/20 0.45
GRIN3A Q8TCU5 2/20 0.45
TAAR1 Q96RJ0 1/20 0.45
CYP1A2 P05177 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367422 1.00 MEN1 (0.54) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL8635101 0.85 MEN1 (0.54) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL8635103 0.85 MEN1 (0.54) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL3067089 0.81 MEN1 (0.50) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL894735 0.81 GRIN2D (0.52) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL887433 0.81 MEN1 (0.50) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL14327772 0.79 PLA2G7 (0.53) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL17293975 0.79 MAOB (0.50) MEN1KMT2AMAPTGRIN2DGRIN3B
SCHEMBL3077773 0.79 PLA2G7 (0.53) MEN1KMT2ALMNAL3MBTL1CA1
SCHEMBL28767552 0.79 KMT2A (0.48) MEN1KMT2ALMNAL3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076285-B2 Lysobactin amides AICURIS GMBH & CO. KG (DE) 2011-12-13 US disclosed
EP-2007794-B1 LYSOBACTIN AMIDES AICURIS GMBH & CO KG (DE) 2011-09-14 EP disclosed
EP-2233468-A1 OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST Nissan Chemical Industries, Ltd. (JP) 2010-09-29 EP disclosed
US-20090203582-A1 LYSOBACTIN AMIDES BAYER HEALTHCARE AG (DE) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203582-A1 LYSOBACTIN AMIDES AADAT, HAMP, DLST MEN1 2317/4885KMT2A 448/4885LMNA 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.